Capgemini Life Sciences and Healthcare’s Post

Hopefully we could land the new initiative in China

Discover the Future of Oncology with the latest #Capgemini Invent report on Innovation Models for Digital Therapeutics (DTx)!    Leading pharma and medical device companies are joining forces with digital health startups to revolutionize the world of healthcare. However, these partnerships must answer business questions that can stimulate Innovation Discovery.    In Advancing Outcomes Design, the first of our two-part report, we examined the context of DTx in oncology from the clinical perspective. In this second part, we delve deep into the evaluation criteria for those same DTx solutions.     Authors @Camille Madelon, @Geoff McCleary, and @Sameera Singh focus on the following key considerations:      ✅ Desirability     ✅ Feasibility    ✅ Viability     Don't miss out on this invaluable resource! Dive into the future of digital therapeutics and uncover the secrets to success in oncology.     🔗 Download and read our new report: https://bit.ly/47pzmXA   Is your organization exploring the potential of digital therapeutics?  🤔 Let us know below! 👇    #DigitalHealth #InnovationInOncology #FutureOfHealthcare #GetTheFutureYouWant 

Discover the Future of Oncology with the latest Capgemini Invent report on Innovation Models for Digital Therapeutics (DTx)!   Leading pharma and medical devices companies are joining forces with digital health startups to revolutionize the world of healthcare. But it is vital these partnerships answer business questions that can stimulate Innovation Discovery.   In Advancing Outcomes Design, the first of our two-part report, we examined the context of DTx in oncology from the clinical perspective. In this second part, we delve deep into the evaluation criteria for those same DTx solutions.   Authors Camille Madelon, Geoff McCleary, and Sameera S. focus on the following key considerations:    ✅ Desirability   ✅ Feasibility  ✅ Viability   Don't miss out on this invaluable resource! Dive into the future of digital therapeutics and uncover the secrets to success in oncology.   🔗 Download and read our new report: Digital Therapeutics in Oncology: Innovation Models https://lnkd.in/gZS4CayN   Is your organization exploring the potential of digital therapeutics? 🤔 Let us know below! 👇   #FutureOfHealthcare #GetTheFutureYouWant

Oncology targeted therapies can significantly benefit from RWE programs, speeding up clinical development, supporting market access, and driving market penetration. Our latest whitepaper provides valuable insights on utilising real-world data for better patient outcomes. Read it here: https://bit.ly/3U0wj3D

Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery via Business Wire Health: Medical Devices News

Rosetta Omics is a French healthcare deeptech startup in a mission is to revolutionize precision medicine, starting with cancer, by integrating multiomics data from patient tumors, clinical records, and advanced machine learning/AI algorithms. Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. At the moment, response rate at first line is very low and physicians need tools like ours to help them. Additionally, we are collaborating with pharmaceutical companies to discover new biomarkers and targets, aiding in drug discovery and patient stratification during clinical trials to accelerate the development of safe and effective cancer treatments. We have already initiated discussions with several leading pharmaceutical firms. Meet Rosetta Omics @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

🔬 Tom's Top 3 - Ep. 2! 🚀 What's happened over the last week... Follow along for the updates! 👉 Q1's Fierce Biotech Layoff Analysis! In 2024, the biotech sector faces ongoing challenges, with persistent layoffs reflecting the aftermath of the 2023 bear market. Despite hurdles, companies remain resilient, navigating uncertain conditions and clinical trial setbacks. 💡 Spanish pharmaceutical giant Ferrer makes waves in AI-driven neuroscience research with a $122 million deal securing rights to Verge Genomics' clinical-stage ALS therapy. This strategic move underscores Ferrer's commitment to innovative treatments, positioning them to address critical medical needs and fill pipeline gaps. 🌟 Ipsen Pharmaceuticals enters the ADC race with a $900 million deal, marking a significant milestone in oncology research. This strategic move highlights Ipsen's dedication to advancing cancer treatment, positioning them alongside industry leaders targeting the ROR1 tumor antigen. Their bold move could be reshaping the competitive landscape in oncology research and development. Join us in celebrating these groundbreaking advancements in the biotech industry! 💼🔬 #Biotech #Innovation #Healthcare #Pharmaceuticals #AI #Oncology #ALS #ADCs

Recognizing the pervasive and systemic reality of multibillion-dollar losses from late-stage clinical trial failures, Predictive Oncology recently announced the expansion of its live-cell tumor platform to de-risk drug discovery and accelerate pipeline development. The company — leveraging its artificial intelligence and machine learning capabilities —  is now mining its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to account for patient heterogeneity ahead of any clinical phase development work. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts more quickly and efficiently. To learn more about how Predictive Oncology has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences

Will you attend Swiss Biotech Day 2024 In Basel? Join our panel of "ADCs and Beyond" on Monday, April 22th. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? Join our panel of varied industry experts and explore these topics. Find out more about the event: https://lnkd.in/dfseDhjc #swissbiotechday #swissbiotechday2024 #ADC #Bioconjugate #ADCdisocvery #ADCdevelopment #ADCmanufacturing #CDMO

The oncology landscape is evolving rapidly—what’s driving these shifting trends? The recent changes in FDA oncology drug approvals have sparked important questions—what’s driving these industry trends, and how are they shaping today’s investment climate? In this article, we interviewed several of our clients to gain their insights on the current oncology landscape and the drivers shaping its future. Read the full article to discover what these changes mean for the future of oncology. https://lnkd.in/ds4h8wjP #Oncology #Biotech #FDA #FDAapprovals #CancerResearch ======== About Theoria Creative Theoria Creative is a marketing firm, enabling life sciences companies to clearly communicate complex science to investors, partners, and peers. We develop communication strategy, messaging, positioning, and prepare a set of illustrated materials that help companies clearly and succinctly articulate their value at high stakes meetings. ========